Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Mianserin, chemically known as 1,2,3,4,10,14b-hexahydro-2-methyl-dibenzo[b,f]azepine, is a tetracyclic antidepressant primarily utilized in the treatment of major depressive disorders. Its molecular formula is C19H20N2, and it is identified by the CAS Registry Number 5886-80-4. First synthesized in the late 1960s and introduced to the market in the early 1970s, Mianserin distinguishes itself from other antidepressants through its unique mechanism of action. Unlike selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), Mianserin functions mainly as an antagonist at central alpha-2 adrenergic autoreceptors and heteroreceptors. By blocking these receptors, it enhances the release of noradrenaline and serotonin in the synaptic cleft, thereby improving mood without directly inhibiting their reuptake. Additionally, it exhibits strong antagonistic activity against histamine H1 receptors and certain serotonin receptors (such as 5-HT2 and 5-HT3), which contributes to its sedative effects and helps alleviate insomnia often associated with depression.
Clinically, Mianserin is valued for its rapid onset of action and favorable side-effect profile compared to older tricyclic agents. It generally lacks significant anticholinergic effects, meaning patients experience fewer issues like dry mouth, constipation, or urinary retention. Furthermore, it does not typically cause weight gain or sexual dysfunction to the same extent as many other antidepressants, making it a preferred option for specific patient populations. While originally widely prescribed across Europe and Asia, its availability has fluctuated in various markets due to regulatory reviews regarding rare cases of agranulocytosis, a serious blood disorder. Despite this, it remains a crucial therapeutic agent for managing moderate to severe depression, particularly where sleep disturbances are prominent. The drug is available in tablet formulations, usually administered orally once daily, often at bedtime to leverage its calming properties. As research continues, Mianserin stands as a significant example of how targeting specific receptor systems can effectively treat complex psychiatric conditions while minimizing traditional side effects associated with monoamine modulation.